Steward Partners Investment Advisory’s Aridis Pharmaceuticals Inc. Common Stock ARDS Stock Holding History

Steward Partners Investment Advisory’s Portfolio ARDS Stock Details ARDS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q4	–	Sell	-1,000	Closed	-$13K	–	2321
2018 Q3	$13K	Buy	+1,000	New	+$12.9K	﹤0.01%	1783

Other funds holding ARDS

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

TRCT

Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return

Steward Partners Investment Advisory's ARDS Position: Q4 2018 in Review

Steward Partners Investment Advisory sold out of Aridis Pharmaceuticals Inc. Common Stock (ARDS) in Q4 2018, closing a stake of 1,000 shares — an estimated $13K sold.

Steward Partners Investment Advisory first reported a position in ARDS in Q3 2018 and held it in 1 quarter. The position peaked at $13K in Q3 2018. 4 funds tracked by Wall St. Rank hold ARDS as of Q4 2018.

Steward Partners Investment Advisory reported no remaining Aridis Pharmaceuticals Inc. Common Stock position as of Q4 2018 after selling out during the quarter.
Steward Partners Investment Advisory sold 1,000 Aridis Pharmaceuticals Inc. Common Stock shares in Q4 2018, an estimated $13K.
Steward Partners Investment Advisory first reported a position in Aridis Pharmaceuticals Inc. Common Stock in Q3 2018 and held it in 1 quarter.
Steward Partners Investment Advisory's Aridis Pharmaceuticals Inc. Common Stock position peaked at $13K in Q3 2018.
4 funds tracked by Wall St. Rank held Aridis Pharmaceuticals Inc. Common Stock as of Q4 2018.

Based on Steward Partners Investment Advisory's 13F filing for Q4 2018, filed 15 Jan 2019.